Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI

Not Applicable

Terminated

Conditions: Malignant Brain Neoplasm

Interventions: Procedure: Arterial Spin Labeling Magnetic Resonance Imaging
Procedure: pH-Weighted amine CEST
Procedure: Oxygen-weighted SAGE-EPI

First Posted Date: 2020-07-07

Last Posted Date: 2022-05-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT04460495

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Phase 1

Recruiting

Conditions: Bladder Carcinoma
Cervical Carcinoma
Cholangiocarcinoma
Hematopoietic and Lymphoid Cell Neoplasm
Hepatocellular Carcinoma
Malignant Adrenal Gland Neoplasm
Malignant Brain Neoplasm
Malignant Pleural Neoplasm
Malignant Skin Neoplasm
Malignant Solid Neoplasm

Interventions: Procedure: Computed Tomography
Drug: Gallium Ga 68 FAPi-46
Procedure: Positron Emission Tomography
Radiation: 18F-FDG

First Posted Date: 2020-07-07

Last Posted Date: 2024-08-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT04459273

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Phase 3

Terminated

Conditions: Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Stage II Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8
Stage III Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Other: Fluorine F 18 DCFPyL
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2020-07-07

Last Posted Date: 2023-01-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 54

Registration Number: NCT04457245

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Phase 1

Active, not recruiting

Conditions: Prostate Carcinoma
Recurrent Prostate Carcinoma
Metastatic Malignant Neoplasm in the Prostate Gland

Interventions: Procedure: Computed Tomography
Other: Gallium Ga 68 FAPi-46
Procedure: Positron Emission Tomography

First Posted Date: 2020-07-07

Last Posted Date: 2024-07-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT04457232

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

Not Applicable

Recruiting

Conditions: Obesity
Malignant Neoplasm

Interventions: Other: Interview
Other: Media Intervention
Other: Questionnaire Administration
Other: Scale Device
Behavioral: Telephone-Based Intervention
Other: Text Message

First Posted Date: 2020-07-01

Last Posted Date: 2024-04-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04453072

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma

Not Applicable

Withdrawn

Conditions: Mesothelioma

Interventions: Procedure: Biospecimen Collection
Procedure: Cryosurgery

First Posted Date: 2020-06-12

Last Posted Date: 2021-06-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT04429204

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Phase 1

Active, not recruiting

Conditions: Resectable Soft Tissue Sarcoma
Resectable Undifferentiated Pleomorphic Sarcoma
Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Stage IB Retroperitoneal Sarcoma AJCC v8
Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Storiform-Pleomorphic Malignant Fibrous Histiocytoma
Myxofibrosarcoma
Pleomorphic Rhabdomyosarcoma
Soft Tissue Fibrosarcoma
Stage II Retroperitoneal Sarcoma AJCC v8

Interventions: Procedure: Definitive Surgical Resection
Biological: Nivolumab
Radiation: Radiation Therapy

First Posted Date: 2020-06-09

Last Posted Date: 2024-03-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT04420975

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Role of Children in Transmission of COVID-19 to Immunocompromised Patients

Terminated

Conditions: Immunosuppression

First Posted Date: 2020-05-29

Last Posted Date: 2023-03-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 109

Registration Number: NCT04407546

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Not Applicable

Withdrawn

Conditions: Prostate Adenocarcinoma
Stage IIA Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Stage II Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8

Interventions: Other: Quality-of-Life Assessment
Radiation: High-Dose Rate Brachytherapy
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2020-05-22

Last Posted Date: 2020-11-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT04399824

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Female Reproductive System Neoplasm
Platinum-Resistant Malignant Female Reproductive System Neoplasm
Recurrent Malignant Female Reproductive System Neoplasm
Refractory Malignant Female Reproductive System Neoplasm

Interventions: Biological: Durvalumab
Radiation: Internal Radiation Therapy
Biological: Tremelimumab

First Posted Date: 2020-05-20

Last Posted Date: 2024-07-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT04395079

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy